Text Size

miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01444560
First received: September 29, 2011
Last updated: October 15, 2012
Last verified: October 2012
History of Changes
  Purpose

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study, the investigators examines the expression profiles of miRNA machinery components such as miRNA maturation and transport factors, microprocessor complex and RISC subunits in cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi.


Condition
Cutaneous Melanoma
Nevi

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

human skin


Enrollment: 21
Study Start Date: December 2008
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Cutaneous Melanoma
Cutaneous Melanoma Metastases
Benign Melanocytic Nevi

Detailed Description:

Patients with cutaneous melanoma, cutaneous melanoma metastases and benign melanocytic nevi were included in the study. Punch biopsies were harvested from the center of the tumors. The miRNA machinery components were detected by quantitative real-time reverse transcriptase polymerase chain reaction.

  Eligibility

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with cutaneous melanoma, cutaneous melanoma metastases, benign melanocytic nevi

Criteria

Inclusion Criteria:

  • cutaneous melanoma
  • cutaneous melanoma metastases
  • benign melanocytic nevi

Exclusion Criteria:

  • other forms of malignancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01444560

Locations
Germany
Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
  More Information

Publications:

Responsible Party: Michael Sand, Postdoc, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01444560     History of Changes
Other Study ID Numbers: microRNA4
Study First Received: September 29, 2011
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Melanoma
Skin Neoplasms
Neoplasm Metastasis
Nevus
Nevus, Pigmented
Nevus, Epithelioid and Spindle Cell
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site
Skin Diseases
Neoplastic Processes
Pathologic Processes
Nevus, Spindle Cell

ClinicalTrials.gov processed this record on May 22, 2013